<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_XPRO101155 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEfx1 jpg ?><?FILEfx2 jpg ?><?FILEfx3 jpg ?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">STAR Protoc</journal-id><journal-id journal-id-type="iso-abbrev">STAR Protoc</journal-id><journal-title-group><journal-title>STAR Protocols</journal-title></journal-title-group><issn pub-type="epub">2666-1667</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8819470</article-id><article-id pub-id-type="pii">S2666-1667(22)00035-1</article-id><article-id pub-id-type="doi">10.1016/j.xpro.2022.101155</article-id><article-id pub-id-type="publisher-id">101155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Protocol for generating a mouse model of gastric MALT lymphoma and the identification of MALT lymphoma cell populations by immunostaining</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Yamamoto</surname><given-names>Koji</given-names></name><email>kyama@pop.med.hokudai.ac.jp</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">4</xref><xref rid="fn2" ref-type="fn">5</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Kondo</surname><given-names>Yasuyuki</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Sugiyama</surname><given-names>Toshiro</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Sakamoto</surname><given-names>Naoya</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan</aff><aff id="aff2"><label>2</label>Research Division of Molecular Targeting Therapy and Prevention of GI Cancer, Hokkaido University Hospital, Sapporo, Hokkaido 060-8638, Japan</aff><aff id="aff3"><label>3</label>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>kyama@pop.med.hokudai.ac.jp</email></corresp><fn id="fn1"><label>4</label><p id="ntpara0010">Technical contact</p></fn><fn id="fn2"><label>5</label><p id="ntpara0015">Lead contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>03</day><month>2</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>18</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>03</day><month>2</month><year>2022</year></pub-date><volume>3</volume><issue>1</issue><elocation-id>101155</elocation-id><permissions><copyright-statement>&#x000a9; 2022 The Author(s)</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p><italic>Helicobacter suis</italic>, a zoonotic infection-related bacterium, induces gastric mucosa-associated lymphoid tissue (MALT) lymphoma in humans and animals. However, a lack of suitable animal models complicates the detailed analysis of this disease. Here, we describe the generation of a gastric MALT lymphoma mouse model. We then detail the use of this model combined with an immunostaining protocol to identify the cell populations that constitute gastric MALT lymphoma. This protocol can be used to identify the constituent cells of human MALT lymphoma.</p><p>For complete details on the use and execution of this profile, please refer to <xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al. (2021)</xref>.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Protocol uses <italic>Helicobacter suis</italic> to induce gastric MALT lymphoma</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Protocol details the generation of a gastric MALT lymphoma mouse model</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Protocol describes an immunostaining approach to identify MALT lymphoma cell populations</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Protocol is applicable in mice with genetic alterations</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p><italic>Helicobacter suis</italic>, a zoonotic infection-related bacterium, induces gastric mucosa-associated lymphoid tissue (MALT) lymphoma in humans and animals. However, a lack of suitable animal models complicates the detailed analysis of this disease. Here, we describe the generation of a gastric MALT lymphoma mouse model. We then detail the use of this model combined with an immunostaining protocol to identify the cell populations that constitute gastric MALT lymphoma. This protocol can be used to identify the constituent cells of human MALT lymphoma.</p></abstract><kwd-group id="kwrds0010"><title>Subject areas</title><kwd>Cell Biology</kwd><kwd>Cancer</kwd><kwd>Immunology</kwd><kwd>Microbiology</kwd><kwd>Microscopy</kwd><kwd>Model Organisms</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Before you begin</title><p id="p0045">All animal experiments were performed in accordance with the Guidelines for Animal Experimentation at Kobe University (Permission No. P130105 and P130106), Hokkaido University (Permission No. 17-0094), and the ARRIVE guidelines. Six-week-old female C57BL/6J mice were purchased from CLEA Japan (C57BL/6JJcl; Tokyo, Japan) and Japan SLC (C57BL/6JJmsSlc; Shizuoka, Japan).</p><sec id="sec1.1"><title>Animals</title><p id="p0050">
<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0055">All mice should be maintained under barrier conditions, in microisolator cages, containing either compressed paper or aspen chip bedding placed on free-standing shelves or individually ventilated cage racks.</p></list-item><list-item id="o0015"><label>2.</label><p id="p0060">All KO mice should be co-housed to homogenize the gut microbiota.</p></list-item><list-item id="o0020"><label>3.</label><p id="p0065">The animals should be maintained under specific pathogen-free conditions in a clean room under a controlled environment at the Institute for Animal Experimentation, Hokkaido University Graduate School of Medicine, or at Kobe University Graduate School of Medicine.</p></list-item><list-item id="o0025"><label>4.</label><p id="p0070">The temperature should be maintained at 22&#x000a0;&#x000b1; 3&#x000b0;C, humidity at 40&#x02013;60%, with a 12&#x000a0;h light/dark cycle.</p></list-item><list-item id="o0030"><label>5.</label><p id="p0075">All mice should have free access to food (standard chow) and water (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>). Preparation 1 should be conducted in the safety cabinet of a BSL2-compatible infectious animal laboratory. The Preparation 2 should be conducted in the safety cabinet of a laboratory facility, which had permission for BSL2-compatible pathogen handling. The Preparations 3 and 4 should be conducted in the laboratory safety cabinet.</p></list-item></list>
</p></sec><sec id="sec1.2"><title>Preparation 1. Procedure for establishing an <italic>H.&#x000a0;suis</italic>-infected gastric MALT lymphoma mouse model</title><p id="p0080">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 24&#x000a0;weeks</bold></p></disp-quote>
</p><p id="p0085">The <italic>H.&#x000a0;suis</italic> was originally obtained from pig stomach (<xref rid="bib10" ref-type="bibr">Yamamoto et&#x000a0;al., 2011</xref>) and maintained in C57BL/6J mice stomachs for 3&#x02013;6&#x000a0;months following the infection (as donors). These methods are established and have been used in several studies (<xref rid="bib15" ref-type="bibr">Mimura et al., 2011</xref>; <xref rid="bib1" ref-type="bibr">Ben Suleiman et&#x000a0;al., 2012</xref>; <xref rid="bib14" ref-type="bibr">Yamamoto et al., 2014</xref>; <xref rid="bib12" ref-type="bibr">Yang et&#x000a0;al., 2015</xref>). Perform the following experiments using these mice.<list list-type="simple" id="olist0015"><list-item id="o0035"><label>6.</label><p id="p0090">Resect the stomach of an <italic>H.&#x000a0;suis</italic>-infected or an uninfected mouse, opening at the outer curvature; wash it with 1&#x000d7; PBS (<xref rid="fig1" ref-type="fig">Figures 1</xref>A and 1B).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Confirmation of <italic>H.&#x000a0;suis</italic> infection using PCR analysis of the stomach homogenates of <italic>H.&#x000a0;suis</italic>-infected mice</p><p>(A) Macroscopic observation of mouse stomach before being opened at the outer curvature from the esophagus. 1 scale; 0.1&#x000a0;cm.</p><p>(B) Macroscopic observation of mouse stomach after being opened at the outer curvature from the esophagus. 1 scale; 0.1&#x000a0;cm.</p><p>(C) Preparation of mouse gastric homogenate. Before: Photograph before preparing the gastric homogenate on cover glass. After: Photograph after preparing the stomach homogenate with cover glass. In the figure on the right, the gastric epithelial tissue is peeled off by the cover glass.</p><p>(D) PCR analysis with <italic>H.&#x000a0;suis</italic> 16S rRNA-specific primers.</p></caption><graphic xlink:href="gr1"/></fig></p></list-item><list-item id="o0040"><label>7.</label><p id="p0095">Transfer the opened stomach to a Petri dish.</p></list-item><list-item id="o0045"><label>8.</label><p id="p0100">Prepare a gastric homogenate from the stomach using 1&#x000a0;mL of 1&#x000d7; PBS on a glass slide.</p></list-item><list-item id="o0050"><label>9.</label><p id="p0105">Use this homogenate as the bacterial inoculum to propagate <italic>H.&#x000a0;suis</italic> infection.</p></list-item><list-item id="o0055"><label>10.</label><p id="p0110">Infect wild-type mice orally with the gastric homogenate.</p></list-item></list><disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Use a glass slide to exert a sufficient pressure for preparing the gastric homogenate (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C).</p></disp-quote><list list-type="simple" id="olist0020"><list-item id="o0060"><label>11.</label><p id="p0115">Administer 0.2&#x000a0;mL of gastric homogenate using a 20G oral sonde to each uninfected mouse.</p></list-item></list><disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Suspend one stomach in 1&#x000a0;mL of 1&#x000d7; PBS; administer 0.2&#x000a0;mL of homogenate per mouse. The homogenate from one stomach could be administered to up to 5 animals.</p></disp-quote><list list-type="simple" id="olist0025"><list-item id="o0065"><label>12.</label><p id="p0120">Use an aliquot of the gastric homogenate to confirm <italic>H.&#x000a0;suis</italic> infection using PCR analysis. (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C, Preparation 2, Preparation 3, and <xref rid="sec8" ref-type="sec">key resources table</xref>).</p></list-item><list-item id="o0070"><label>13.</label><p id="p0125">After confirming <italic>H.&#x000a0;suis</italic> infection, continue maintaining the infected mice for 6&#x000a0;months to develop a gastric MALT lymphoma model. In this study, the end-point of the experiment was at 6&#x000a0;months.</p></list-item></list></p></sec><sec id="sec1.3"><title>Preparation 2. Extraction of DNA from the stomach of <italic>H.&#x000a0;suis</italic>-infected mice</title><p id="p0130">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x000a0;days</bold></p></disp-quote>
<list list-type="simple" id="olist0030"><list-item id="o0075"><label>14.</label><p id="p0135">Add the specified amounts of Tris-HCl, SDS, and Proteinase K (<xref rid="tbl1" ref-type="table">Table 1</xref>) to the gastric homogenate to enable cell lysis.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Lysis of mouse-derived stomach</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>1&#x000a0;M Tris-HCl (pH 7.5)</td><td>10&#x000a0;mM</td><td>4&#x000a0;&#x003bc;L</td></tr><tr><td>10% SDS</td><td>1%</td><td>40&#x000a0;&#x003bc;L</td></tr><tr><td>Proteinase K (20&#x000a0;mg/mL)</td><td>200&#x000a0;&#x003bc;g/mL</td><td>4&#x000a0;&#x003bc;L</td></tr><tr><td>Gastric homogenate</td><td>&#x02013;</td><td>352&#x000a0;&#x003bc;L</td></tr><tr><td>Total</td><td>&#x02013;</td><td>400&#x000a0;&#x003bc;L</td></tr></tbody></table></table-wrap></p></list-item><list-item id="o0080"><label>15.</label><p id="p0140">Incubate the mixture at 55&#x000b0;C for 12&#x02013;24&#x000a0;h in a heat block.</p></list-item><list-item id="o0085"><label>16.</label><p id="p0145">Add 400&#x000a0;&#x003bc;L of phenol/chloroform/isoamyl alcohol (PCI) (25:24:1) to the lysate and centrifuge at 13200&#x000d7;<italic>g</italic> at 4&#x000b0;C for 5&#x000a0;min.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> The PCI mixture is a non-medicinal toxic substance and is always stored in the dark at 4&#x000b0;C in locked shelves.</p></disp-quote>
<list list-type="simple" id="olist0035"><list-item id="o0090"><label>17.</label><p id="p0150">After centrifugation, collect 300&#x000a0;&#x003bc;L of supernatant and add 30&#x000a0;&#x003bc;L of 3&#x000a0;M sodium acetate (pH 5.2) and 825&#x000a0;&#x003bc;L of 99% ethanol.</p></list-item><list-item id="o0095"><label>18.</label><p id="p0155">Centrifuge the mixture at 15500&#x000d7;<italic>g</italic> at 4&#x000b0;C for 10&#x000a0;min.</p></list-item><list-item id="o0100"><label>19.</label><p id="p0160">After centrifugation, discard the supernatant and add 1&#x000a0;mL of 75% ethanol, taking care to not break the pellet.</p></list-item><list-item id="o0105"><label>20.</label><p id="p0165">Centrifuge the mixture at 15500&#x000d7;<italic>g</italic> at 4&#x000b0;C for 5&#x000a0;min.</p></list-item><list-item id="o0110"><label>21.</label><p id="p0170">After centrifugation, discard the supernatant, and place the tubes on a bench with the lid open and air dry the pellet at room temperature for 10&#x000a0;min.</p></list-item><list-item id="o0115"><label>22.</label><p id="p0175">Add Tris-EDTA (TE) buffer (200&#x02013;500&#x000a0;&#x003bc;L; pH 8.0) to the pellet and incubate at 37&#x000b0;C, in a heat block for 5&#x02013;10&#x000a0;min.</p></list-item><list-item id="o0120"><label>23.</label><p id="p0180">Use the extracted DNA for PCR analysis.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> DNA concentration and quality is evaluated using a spectrophotometer (Nanodrop). If the A260/230 ratio is lower than 1, it indicates the presence of contaminants, such as phenol. If the A260/230 ratio is less than 1, purify the DNA again. Ensure that the A260/A280 ratio is between 1.5 and 2.0; ideally, it should be 1.8. The above evaluation is highly recommended because the quality of DNA affects the PCR. After measuring the concentration of the extracted DNA, the DNA is diluted to 1000&#x000a0;ng/&#x003bc;L, and 1000&#x000a0;ng of DNA is used for the PCR analysis.</p></disp-quote>
</p></sec><sec id="sec1.4"><title>Preparation 3. PCR analysis conditions for confirming <italic>H.&#x000a0;suis</italic> infection</title><p id="p0185">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 3&#x02013;4 h</bold></p></disp-quote>
<list list-type="simple" id="olist0040"><list-item id="o0125"><label>24.</label><p id="p0190">Preparation of PCR amplification mix</p></list-item></list>
</p><p id="p0195">The details of the reagents used and the PCR cycling conditions are shown in <xref rid="tbl2" ref-type="table">Tables 2</xref> and <xref rid="tbl3" ref-type="table">3</xref>.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Preparation of PCR reaction mix</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>PCR-Grade Water</td><td>&#x02013;</td><td>40&#x000a0;&#x003bc;L</td></tr><tr><td>10&#x000d7; Advantage 2 PCR Buffer</td><td>10&#x000d7;</td><td>5&#x000a0;&#x003bc;L</td></tr><tr><td>50&#x000d7; dNTP Mix (10&#x000a0;mM)</td><td>50&#x000d7;</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>5&#x02032; primer (10&#x000a0;&#x003bc;M)</td><td>10&#x000a0;&#x003bc;M</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>3&#x02032; primer (10&#x000a0;&#x003bc;M)</td><td>10&#x000a0;&#x003bc;M</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>50&#x000d7; Advantage 2 Polymerase Mix</td><td>50&#x000d7;</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>DNA Template (1000&#x000a0;ng/&#x003bc;L)</td><td>1000&#x000a0;ng</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>Total volume</td><td>&#x02013;</td><td>50&#x000a0;&#x003bc;L</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>PCR cycling conditions</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Steps</th><th>Temperature</th><th>Time</th><th>Cycles</th></tr></thead><tbody><tr><td>Initial Denaturation</td><td>95&#x000b0;C</td><td>1&#x000a0;min</td><td>1</td></tr><tr><td>Denaturation</td><td>95&#x000b0;C</td><td>30 s</td><td rowspan="2">25&#x02013;35</td></tr><tr><td>Annealing</td><td>68&#x000b0;C</td><td>1&#x000a0;min</td></tr><tr><td>Final extension</td><td>68&#x000b0;C</td><td>1&#x000a0;min</td><td>1</td></tr><tr><td>Hold</td><td>4&#x000b0;C</td><td colspan="2">Forever</td></tr></tbody></table></table-wrap></p></sec><sec id="sec1.5"><title>Preparation 4. Gel electrophoresis</title><p id="p0200">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1 h</bold></p></disp-quote>
<list list-type="simple" id="olist0045"><list-item id="o0130"><label>25.</label><p id="p0205">Prepare agarose mini-gel</p></list-item><list-item id="o0135"><label>26.</label><p id="p0210">Separate the PCR products on 1.5% agarose mini-gels in TAE buffer (40&#x000a0;mM Tris-acetate and 1&#x000a0;mM EDTA).</p></list-item><list-item id="o0140"><label>27.</label><p id="p0215">Conduct electrophoresis at 100 V, using a 100&#x000a0;bp DNA ladder as the standard.</p></list-item><list-item id="o0145"><label>28.</label><p id="p0220">Following electrophoresis, stain the gels with a DNA binding dye, such as ethidium bromide.</p></list-item><list-item id="o0150"><label>29.</label><p id="p0225">Place the gel in ethidium bromide buffer and stain for 15&#x000a0;min<bold>.</bold></p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Ethidium bromide is a powerful mutagen; therefore, be careful when storing and handling it. Wear disposable gloves when handling. Ethidium bromide solution should be stored at room temperature (20&#x000b0;C<bold>&#x02013;</bold>25&#x000b0;C) used for staining agarose gels, and disposed immediately after inactivation. For inactivating the liquid waste after ethidium bromide staining, use EtBr Destroyer, which effectively decomposes and destroys ethidium bromide, making it non-mutagenic. Ethidium bromide was used in this study; however, as an alternative, nucleic acid staining reagents (GelRed&#x02122; &#x00026; GelGreen&#x02122; (Biotium, Inc.)) with low toxicity, high sensitivity, and excellent thermal stability could be used.</p></disp-quote>
<list list-type="simple" id="olist0050"><list-item id="o0155"><label>30.</label><p id="p0230">Photograph the gel under a UV transilluminator (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D).</p></list-item></list>
</p></sec></sec><sec id="sec8"><title>Key resources table</title><p id="p0465">
<table-wrap position="float" id="undtbl8"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Polyclonal rabbit anti-<italic>Helicobacter pylori</italic> (1:20)</td><td>DAKO</td><td>Cat#B047129-1; RRID: AB_2313773</td></tr><tr><td>Purified rat anti-mouse CD45R (1:20)</td><td>BD Biosciences</td><td>Cat#553086; RRID: AB_394616</td></tr><tr><td>Purified rat anti-mouse CD4 (1:20)</td><td>BD Biosciences</td><td>Cat#550280; RRID: AB_393575</td></tr><tr><td>Purified rat anti-mouse F4/80 (1:20)</td><td>BD Biosciences</td><td>Cat#565409; RRID: AB_2739222</td></tr><tr><td>Purified anti-mouse NK-1.1 (1:20)</td><td>BioLegend</td><td>Cat#108702; RRID: AB_313389</td></tr><tr><td>FITC hamster anti-mouse CD11c (1:20)</td><td>BD Biosciences</td><td>Cat#553801; RRID: AB_395060</td></tr><tr><td>Purified rat anti-mouse follicular dendritic cell (1:20)</td><td>BD Biosciences</td><td>Cat#551320; RRID: AB_394151</td></tr><tr><td>Monoclonal rat anti-mouse Ep-CAM (G8.8) (1:20)</td><td>BioLegend</td><td>Cat#118202; RRID: AB_1089026</td></tr><tr><td>Biotin-conjugated anti-mouse TLR4 (1:20-50)</td><td>Abcam</td><td>Cat#ab6788; RRID: AB_954885</td></tr><tr><td>DyLight 488-conjugated streptavidin (1:200)</td><td>Jackson ImmunoResearch Laboratories, Inc</td><td>Cat#016-480-084; RRID: AB_2313773</td></tr><tr><td>Goat anti-rat IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 488 (1:200)</td><td>Thermo Fisher Scientific</td><td>Cat#A-11006; RRID: AB_2534074</td></tr><tr><td>Goat anti-rat IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 546 (1:200)</td><td>Thermo Fisher Scientific</td><td>Cat#A-11081; RRID: AB_141738</td></tr><tr><td>Goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 488 (1:200)</td><td>Thermo Fisher Scientific</td><td>Cat#A-11008; RRID: AB_143165</td></tr><tr><td>Alexa Fluor 647 phalloidin (1:200)</td><td>Thermo Fisher Scientific</td><td>Cat#A22287</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Bacterial and virus strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td><italic>Helicobacter suis</italic></td><td>Isolated from pig</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>100&#x000a0;bp DNA Ladder (Dye Plus)</td><td>TaKaRa Bio</td><td>Cat#3422A</td></tr><tr><td>Acetone</td><td>Wako</td><td>Cat#016-00346</td></tr><tr><td>NORMAL GOAT SERUM</td><td>VECTOR</td><td>Cat#S-1000; RRID: AB_2336615</td></tr><tr><td>Tissue-Tek O.C.T. Compound</td><td>Sakura Finetek</td><td>Cat#4583</td></tr><tr><td>50x TAE</td><td>NIPPON GENE</td><td>Cat#313-90035</td></tr><tr><td>Agarose S</td><td>Wako</td><td>Cat#312-01193</td></tr><tr><td>Ethidium Bromide Solution</td><td>Invitrogen</td><td>Cat#15585-011</td></tr><tr><td>Prolong Diamond (fluorescent mounting medium)</td><td>Invitrogen</td><td>Cat#P36961</td></tr><tr><td>Ethanol (99.5%)</td><td>Wako</td><td>Cat#057-00456</td></tr><tr><td>TE (pH 8.0)</td><td>NIPPON GENE</td><td>Cat#316-90025</td></tr><tr><td>1M Tris-HCl (pH7.5)</td><td>NIPPON GENE</td><td>Cat#318-90225</td></tr><tr><td>10% SDS Solution</td><td>NIPPON GENE</td><td>Cat#311-90271</td></tr><tr><td>3M Sodium Acetate (pH 5.2)</td><td>NIPPON GENE</td><td>Cat#316-90081</td></tr><tr><td>Phenol/Chloroform/Isoamyl alcohol (25:24:1)</td><td>NIPPON GENE</td><td>Cat#311-90151</td></tr><tr><td>Proteinase K</td><td>AmBion</td><td>Cat#AM2546</td></tr><tr><td>Advantage 2 PCR Kit</td><td>TaKaRa Bio</td><td>Cat#639206</td></tr><tr><td>PBS</td><td>Sigma-Aldrich</td><td>Cat#P3813</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental models: Organisms/strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Mouse: WT: C57BL/6J</td><td>CLEA Japan Inc.</td><td>C57BL/6JJcl</td></tr><tr><td>Mouse: WT: C57BL/6J</td><td>Japan SLC</td><td>C57BL/6JJmsSlc</td></tr><tr><td>Mouse: <italic>Myd88</italic> KO: <italic>Myd88</italic> deficient</td><td>Oriental Yeast Co., Ltd.</td><td>B6.129-Myd88<sup>tm1Aki</sup>/Obs<break/>RRID: IMSR_OBS:1</td></tr><tr><td>Mouse: <italic>Trif</italic> KO: <italic>Trif</italic> deficient</td><td>Oriental Yeast Co., Ltd.</td><td>B6.129P2-Trif<sup>tm1Aki</sup>/Obs<break/>IMSR_OBS:16</td></tr><tr><td>Mouse: <italic>Myd88</italic>/<italic>Trif</italic> DKO: <italic>Myd88/Trif</italic> deficient</td><td>Oriental Yeast Co., Ltd.</td><td>B6.129P2-MyD88/Trif<sup>tm1Aki</sup>/Obs RRID: IMSR_OBS:22</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Oligonucleotides</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td><italic>H.&#x000a0;suis</italic> 16S rRNA primer Forward; 5&#x02032;-TTGGGAGGCTTTGTCTTTCCA-3&#x02032;</td><td><xref rid="bib10" ref-type="bibr">Yamamoto et al., 2011</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21397035/" id="intref0015">https://pubmed.ncbi.nlm.nih.gov/21397035/</ext-link></td></tr><tr><td><italic>H.&#x000a0;suis</italic> 16S rRNA primer Reverse; 5&#x02032; -GATTAGCTCTGCCTCGCGGCT-3&#x02032;</td><td><xref rid="bib10" ref-type="bibr">Yamamoto et al., 2011</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21397035/" id="intref0020">https://pubmed.ncbi.nlm.nih.gov/21397035/</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>LSM Image Browser</td><td>Carl Zeiss Co. Ltd</td><td><ext-link ext-link-type="uri" xlink:href="https://www.embl.de/eamnet/html/body_image_browser.html" id="intref0025">https://www.embl.de/eamnet/html/body_image_browser.html</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Other</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Confocal laser-scanning microscope</td><td>Carl Zeiss Co. Ltd</td><td>Cat#LSM710</td></tr><tr><td>Thermal cycler</td><td>Applied Biosystems</td><td>Cat#2720</td></tr><tr><td>SLIDE GRASS DRYER SGD-F</td><td>ASONE</td><td>Cat#1-4178-01</td></tr><tr><td>Cryostat</td><td>Leica Biosystems</td><td>Cat# CM1850</td></tr><tr><td>Incubation Chamber</td><td>COSMO BIO CO,. LTD</td><td>N/A</td></tr><tr><td>Tissue-Tek Cryomold (15&#x000a0;mm&#x000d7;15&#x000a0;mm&#x000d7;5&#x000a0;mm)</td><td>Sakura Finetek</td><td>Cat#4566</td></tr><tr><td>Mupid-2plus</td><td>ASONE</td><td>N/A</td></tr><tr><td>FUSION SOLO S (UV trans-illuminator)</td><td>VILBER</td><td>N/A</td></tr><tr><td>Animal Feeding Needles (20G) (Oral sonde)</td><td>Natsume Seisakusho Co., Ltd.</td><td>Cat#KN-348-20G-50</td></tr><tr><td>Matsunami Cover Glass (No.1) 24 x 32mm</td><td>MATSUNAMI GLASS IND., LTD</td><td>Cat#C024321</td></tr><tr><td>Spectrophotometer</td><td>DeNovix</td><td>Cat#DS-11</td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec2"><title>Materials and equipment</title><sec id="sec2.1"><title>Materials</title><p id="p0235">
<table-wrap position="float" id="undtbl1"><caption><p>Preparation of 75% ethanol (Use immediately after dilution)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>99.5% ethanol</td><td>75%</td><td>75.4&#x000a0;mL</td></tr><tr><td>Water</td><td>&#x02013;</td><td>24.6&#x000a0;mL</td></tr><tr><td>Total</td><td>&#x02013;</td><td>100&#x000a0;mL</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="undtbl2"><caption><p>Preparation of 1xTAE buffer (Use immediately after dilution)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>50&#x000d7; TAE (Store at room temperature)</td><td>1&#x000d7;</td><td>1&#x000a0;mL</td></tr><tr><td>Water</td><td>&#x02013;</td><td>49&#x000a0;mL</td></tr><tr><td>Total</td><td>&#x02013;</td><td>50&#x000a0;mL</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="undtbl3"><caption><p>Preparation of 2% agarose mini-gels (Use immediately after preparation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>1&#x000d7; TAE</td><td>&#x02013;</td><td>25&#x000a0;mL</td></tr><tr><td>Agarose S</td><td>2%</td><td>0.5 g</td></tr><tr><td>Total</td><td>&#x02013;</td><td>25&#x000a0;mL</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="undtbl4"><caption><p>Preparation of ethidium bromide buffer (Use immediately after dilution)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Ethidium bromide (Store at room temperature)</td><td>&#x02013;</td><td>20&#x000a0;&#x003bc;L</td></tr><tr><td>Water</td><td>&#x02013;</td><td>200&#x000a0;mL</td></tr><tr><td>Total</td><td>&#x02013;</td><td>200&#x000a0;mL</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="undtbl5"><caption><p>Preparation of 10% goat serum (After dilution, use immediately without storing)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Goat serum</td><td>10%</td><td>10&#x000a0;&#x003bc;L</td></tr><tr><td>PBS</td><td/><td>90&#x000a0;&#x003bc;L</td></tr><tr><td>Total</td><td>&#x02013;</td><td>100&#x000a0;&#x003bc;L</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="undtbl6"><caption><p>Preparation of Anti-mouse primary antibody</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Anti-mouse CD45R antibody (1: 20)</td><td>1: 20</td><td>5&#x000a0;&#x003bc;L</td></tr><tr><td>PBS</td><td>&#x02013;</td><td>95&#x000a0;&#x003bc;L</td></tr><tr><td>Total</td><td>&#x02013;</td><td>100&#x000a0;&#x003bc;L</td></tr></tbody></table></table-wrap>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> If a sample requires staining with multiple antibodies targeting different proteins, it is essential to use antibodies raised in different hosts.</p></disp-quote>
<table-wrap position="float" id="undtbl7"><caption><p>Preparation of secondary antibody</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Anti-rat igG Alexa488 (1: 200)</td><td>1: 200</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>Alexa Fluor 647 phalloidin (1:200)</td><td>1: 200</td><td>1&#x000a0;&#x003bc;L</td></tr><tr><td>PBS</td><td>&#x02013;</td><td>198&#x000a0;&#x003bc;L</td></tr><tr><td>Total</td><td>&#x02013;</td><td>200&#x000a0;&#x003bc;L</td></tr></tbody></table></table-wrap>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Multiple secondary antibodies from different hosts could be added. In that case, the amount of PBS is adjusted according to the amount of primary antibody added.</p></disp-quote>
</p><p id="p0240">Equipment:<list list-type="simple" id="ulist0015"><list-item id="u0030"><label>&#x02022;</label><p id="p0245">Confocal laser-scanning microscope (Carl Zeiss, Oberkochen, Germany)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> Any other confocal laser-scanning microscope could be used.</p></disp-quote><list list-type="simple" id="ulist0020"><list-item id="u0035"><label>&#x02022;</label><p id="p0250">CM1850 Cryostat (Leica, Germany)</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p0255">Incubation chamber (Cosmo Bio Co. Ltd., Tokyo, Japan)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> Any other incubation chamber could be used.</p></disp-quote><list list-type="simple" id="ulist0025"><list-item id="u0045"><label>&#x02022;</label><p id="p0260">Slide grass dryer (As one Corporation)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> Any other slide glass dryer could be used.</p></disp-quote><list list-type="simple" id="ulist0030"><list-item id="u0050"><label>&#x02022;</label><p id="p0265">Oral sonde (Natsume Seisakusho Co., Ltd. Tokyo, JAPAN)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> Any other oral sonde could be used.</p></disp-quote><list list-type="simple" id="ulist0035"><list-item id="u0055"><label>&#x02022;</label><p id="p0270">Thermal cycler (Applied Biosystems)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> This protocol is based on a PCR procedure performed with a thermal cycler (Applied Biosystems). Gradient TurboCycler 2 (Blue-Ray Biotech) was also used.</p></disp-quote><list list-type="simple" id="ulist0040"><list-item id="u0060"><label>&#x02022;</label><p id="p0275">UV trans-illuminator (VILBER)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> ImageQuant LAS 4000 (GE Healthcare Life Science) could be used.</p></disp-quote><list list-type="simple" id="ulist0045"><list-item id="u0065"><label>&#x02022;</label><p id="p0280">Mupid-2plus (Takara Bio Inc.)</p></list-item></list><disp-quote><p><bold><italic>Alternatives:</italic></bold> WSE-1710Submerge-Mini (ATTO Corporation) could be used.</p></disp-quote></p></sec></sec><sec id="sec3"><title>Step-by-step method details</title><sec id="sec3.1"><title>Preparing a frozen block of mouse stomach</title><p id="p0285">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 6&#x000a0;months</bold></p></disp-quote>
<list list-type="simple" id="olist0055"><list-item id="o0160"><label>1.</label><p id="p0290">Six months after <italic>H.&#x000a0;suis</italic> infection, sacrifice all mice through cervical dislocation under anesthesia.</p></list-item><list-item id="o0165"><label>2.</label><p id="p0295">Resect the stomachs, opening at the outer curvature (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Preparing frozen samples of mouse stomach</p><p>Photograph after resecting the stomach, opened at the outer curvature. Scale bar; 1.0&#x000a0;cm</p></caption><graphic xlink:href="gr2"/></fig></p></list-item><list-item id="o0170"><label>3.</label><p id="p0300">Free half of the stomach in cryo-embedding compound (O.C.T) to be cut into sections (Sakura Finetek, Tokyo, Japan).</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> The OCT compound is added according to the size of the Cryomold (15&#x000a0;mm &#x000d7; 15&#x000a0;mm &#x000d7; 5&#x000a0;mm).</p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> The cryomolds are stored at &#x02212;80&#x000b0;C until sectioning.</p></disp-quote>
</p></sec><sec id="sec3.2"><title>Preparing a frozen sliced sample</title><p id="p0305">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: &#x0223c;1 h</bold></p></disp-quote>
</p><p id="p0310">The objective of this step was to create a sliced sample of 10-&#x003bc;m thickness.<list list-type="simple" id="olist0060"><list-item id="o0175"><label>4.</label><p id="p0315">Set the inside temperature of the device between &#x02212;15&#x000b0;C and &#x02212;20&#x000b0;C.</p></list-item></list><disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> When preparing a sliced sample, ensure that the tissue does not crack or break after sectioning</p></disp-quote><list list-type="simple" id="olist0065"><list-item id="o0180"><label>5.</label><p id="p0320">After slicing, immediately place the tissue sections in a staining vat containing 200&#x000a0;mL of acetone for about 1 s, dry the sections using an air dryer, and store at &#x02212;30&#x000b0;C until staining.</p></list-item></list><disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> If the sliced sample is not stored at &#x02212;30&#x000b0;C, start the staining immediately using the following procedure.</p></disp-quote></p></sec><sec id="sec3.3"><title>Immunostaining protocol</title><p id="p0325">
<disp-quote><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: &#x0223c;24 h</bold></p></disp-quote>
<list list-type="simple" id="olist0070"><list-item id="o0185"><label>6.</label><p id="p0330">Air dry the tissue sections for 1&#x02013;2&#x000a0;h at room temperature.</p></list-item><list-item id="o0190"><label>7.</label><p id="p0335">Use a staining vat containing 200&#x000a0;mL of acetone to fix tissue sections. Fix the sections in acetone for 5&#x02013;10&#x000a0;min.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> This fixation step should be done inside the chemical hood.</p></disp-quote>
<list list-type="simple" id="olist0075"><list-item id="o0195"><label>8.</label><p id="p0340">Allow the sections to stand in a staining vat containing 200&#x000a0;mL of 1&#x000d7; PBS for 3&#x000a0;min, for each wash. Repeat the wash thrice.</p></list-item><list-item id="o0200"><label>9.</label><p id="p0345">Remove the excess 1&#x000d7; PBS from the section using a wipe.</p></list-item><list-item id="o0205"><label>10.</label><p id="p0350">Add 100&#x000a0;mL of 10% goat serum drop-wise onto the section and incubate for 30&#x000a0;min for blocking, in a humid chamber.</p></list-item><list-item id="o0210"><label>11.</label><p id="p0355">Wash the sections thrice with PBS, incubating for 3&#x000a0;min each time.</p></list-item><list-item id="o0215"><label>12.</label><p id="p0360">After removing excess 1&#x000d7; PBS from the section, add 100&#x000a0;&#x003bc;L of primary antibody (diluted 1:20&#x02013;50 with 1&#x000d7; PBS) drop-wise and incubate at room temperature for 2&#x000a0;h (or at 4&#x000b0;C for 12&#x02013;24&#x000a0;h in a humid chamber.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Be careful not to let the sample dry out, because this could affect the staining. After removing excess PBS from the section, it is highly recommended to stain the samples immediately with the respective antibody.</p></disp-quote>
<list list-type="simple" id="olist0080"><list-item id="o0220"><label>13.</label><p id="p0365">Wash the sections thrice with 1&#x000d7; PBS, incubating for 3&#x000a0;min each time.</p></list-item><list-item id="o0225"><label>14.</label><p id="p0370">Remove the excess 1&#x000d7; PBS from the section. Add 100&#x000a0;&#x003bc;L of secondary antibody (diluted in 1&#x000d7; PBS) drop-wise and incubate at room temperature for 1&#x000a0;h in a dark room in a humid chamber.</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Be careful not to let the sample dry out, because this could affect the staining.</p></disp-quote>
<list list-type="simple" id="olist0085"><list-item id="o0230"><label>15.</label><p id="p0375">Wash the sections thrice with 1&#x000d7; PBS incubating for 3&#x000a0;min each time.</p></list-item><list-item id="o0235"><label>16.</label><p id="p0380">After removing the excess 1&#x000d7; PBS from the section, add 100&#x000a0;&#x003bc;L of fluorescent mounting medium drop-wise, and cover the tissue section with a coverslip (Size; 24&#x000a0;&#x000d7; 32&#x000a0;mm).</p></list-item></list>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Be careful not to let the sample dry out, because this could cause the fading of the fluorescence.</p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> After adding the mounting medium, ensure there are no bubbles in the sample. If there are air bubbles, use a PIPETMAN&#x000ae;pipetman to completely remove them by aspiration.</p></disp-quote>
<disp-quote><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> After encapsulating the mounting medium, the sample can be stored at 4&#x000b0;C for 2&#x02013;3&#x000a0;days.</p></disp-quote>
<list list-type="simple" id="olist0090"><list-item id="o0240"><label>17.</label><p id="p0385">Observe fluorescence signals under a confocal laser-scanning microscope.</p></list-item><list-item id="o0245"><label>18.</label><p id="p0390">Use a suitable software, such as LSM Image Browser, to analyze the images. Set the pixels in the x-y plane to 1024&#x000a0;&#x000d7; 1024 pixels at a pixel size of 0.83&#x000a0;&#x003bc;m/pixel.</p></list-item></list>
</p></sec></sec><sec id="sec4"><title>Expected outcomes</title><p id="p0395"><italic>Myd88</italic> knockout (KO), <italic>Trif</italic> KO, and <italic>Myd88</italic>/<italic>Trif</italic> double knockout (DKO) mice were infected with <italic>H.&#x000a0;suis</italic> for 6&#x000a0;months, to investigate the roles of these proteins in the formation of MALT lymphoma. We detected the formation of the gastric MALT lymphoma mainly in the stomachs of <italic>H.&#x000a0;suis</italic>-infected WT and <italic>Myd88</italic> KO mice but not in the stomachs of <italic>Trif</italic> KO and <italic>Myd88</italic>/<italic>Trif</italic> DKO mice (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A) (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>). The incidence of gastric MALT lymphoma is similar between WT and MyD88 KO mice. The immunocompetent cells that infiltrate follicles after <italic>H.&#x000a0;suis</italic> infection were visualized using immunofluorescence staining with antibodies of interest. Consistent with our recent reports (<xref rid="bib14" ref-type="bibr">Yamamoto et al., 2014</xref>; <xref rid="bib12" ref-type="bibr">Yang et&#x000a0;al., 2015</xref>), B cells, CD4<sup>+</sup> T&#x000a0;cells, Dendritic Cells (DCs), and Follicular dendritic Cells (FDCs), but not natural killer cells and monocytes/macrophages, were identified in the gastric lymphoid follicles of <italic>H.&#x000a0;suis</italic>-infected WT and <italic>Myd88-</italic>KO mice. In contrast, the infiltration of these cells was less in the <italic>H.&#x000a0;suis</italic>-infected <italic>Trif</italic>-KO and <italic>Myd88</italic>/<italic>Trif</italic>-DKO mice, with the detection of fewer follicles (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B) (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>). Immunostaining showed that <italic>H.&#x000a0;suis</italic> was mainly located in the gastric mucosa of infected WT and <italic>Myd88</italic>-KO mice, but not in that of <italic>Trif</italic>-KO and <italic>Myd88</italic>/<italic>Trif-</italic>DKO mice (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C) (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>). A round structure infiltrated with lymphocytes is observed in the stomach of mice infected with <italic>H.&#x000a0;suis</italic>; this is not found in normal gastric epithelial tissue. We refer to this as a follicle. <italic>H.&#x000a0;suis</italic> was not localized in the lymphoid follicles. (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C) (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>). In addition, immunostaining results indicated that TLR4 was mainly localized in the gastric mucosa of <italic>H.&#x000a0;suis</italic>-infected WT and <italic>Myd88</italic> KO mice but not in the gastric MALT lymphoma (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D) (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>). Moreover, epithelial cell adhesion molecule (EpCAM), a marker of gastric epithelial tissues, was detected in the gastric epithelium of mice after <italic>Helicobacter</italic> infection (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E) (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>; <xref rid="bib8" ref-type="bibr">Shibata et&#x000a0;al., 2010</xref>; <xref rid="bib2" ref-type="bibr">El-Zaatari et&#x000a0;al., 2013</xref>; <xref rid="bib3" ref-type="bibr">Lina et&#x000a0;al., 2013</xref>; <xref rid="bib9" ref-type="bibr">Shigematsu et&#x000a0;al., 2013</xref>).<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Immunofluorescence staining of mouse stomach</p><p>C57BL/6J WT, <italic>Myd88-</italic>KO, <italic>Trif</italic>-KO, and <italic>Myd88</italic>/<italic>Trif</italic>-DKO mice (n&#x000a0;= 5/group) were analyzed 6&#x000a0;months after <italic>H.&#x000a0;suis</italic> infection.</p><p>(A) Histological examination and mean number of gastric lymphoid follicles. Original magnification, 200&#x000d7;; Scale bar; 100&#x000a0;&#x003bc;m, (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>).</p><p>(B) Immunofluorescence of immunocompetent cells in the stomach (n&#x000a0;= 5 per group). B220-positive cells (B cells), CD4-positive cells (helper T&#x000a0;cells), CD11c-positive cells (dendritic cells), follicular dendritic cells, NK1.1-positive cells (natural killer cells), and phalloidin (F-actin) positive cells were analyzed using confocal microscopy. Magnification, 100&#x000d7;; Scale bar; 100&#x000a0;&#x003bc;m, (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>).</p><p>(C) Immunofluorescence of <italic>H.&#x000a0;suis</italic> distribution (n&#x000a0;= 5/group) after confocal microscopy. Magnification, 100&#x000d7;; Scale bar; 100&#x000a0;&#x003bc;m, (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>).</p><p>(D) Immunofluorescence of TLR4-expressing cells analyzed using confocal microscopy. Magnification, 100&#x000d7;; Scale bar; 100&#x000a0;&#x003bc;m, (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>).</p><p>(E) Analysis of EpCAM-positive cells in the stomachs of <italic>H.&#x000a0;suis</italic>-infected WT mice. Magnification, 100&#x000d7;. The formation of gastric lymphoid follicles is indicated using the dotted lines. Representative images are shown. Magnification, 100&#x000d7;; Scale bar; 100&#x000a0;&#x003bc;m, (<xref rid="bib11" ref-type="bibr">Yamamoto et&#x000a0;al., 2021</xref>).</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec5"><title>Limitations</title><p id="p0400">The limitation of our study was the failure to identify cells that infiltrated the stomach by performing similar immunostaining of human gastric MALT lymphoma patient specimens. <italic>H.&#x000a0;suis</italic>, similar to <italic>Helicobacter pylori</italic>, is a gram-negative bacterium that colonizes the stomach of humans and various animals, such as pigs, dogs, and cats (<xref rid="bib6" ref-type="bibr">O'Rourke et&#x000a0;al., 2004</xref>; <xref rid="bib7" ref-type="bibr">Priestnall et&#x000a0;al., 2004</xref>; <xref rid="bib10" ref-type="bibr">Yamamoto et&#x000a0;al., 2011</xref>). <italic>H.&#x000a0;suis</italic> is strongly associated with gastric MALT lymphoma (<xref rid="bib4" ref-type="bibr">Nakamura et&#x000a0;al., 2007</xref>; <xref rid="bib5" ref-type="bibr">Okamura et&#x000a0;al., 2013</xref>), and it has been detected in human patients. TLR4&#x02013;TRIF is activated in the gastric epithelial cells following <italic>H.&#x000a0;suis</italic> infection; this induces the production of type 1 Interferon (IFN), which interacts with the IFNAR expressed on gastric B cells. Gastric MALT lymphoma is formed in response to the IFN-&#x003b3; production from gastric B cells. In addition, the IFN-&#x003b3; produced from B cells promotes the formation of gastric MALT lymphoma by stimulating IFNGR on B cells to further increase IFN-&#x003b3; production through feedback regulation. (Yamamoto k et&#x000a0;al., 2021). Human MALT-type outer marginal zone B-cell lymphoma expresses only TLR4 (<xref rid="bib16" ref-type="bibr">Adam et al., 2008</xref>). Therefore, the activation of the TLR4 signaling pathway is associated with gastric MALT lymphoma formation in both humans and in this animal model. However, further investigation is needed to determine whether the gastric MALT lymphoma development process shown in the <italic>H.&#x000a0;suis</italic>-infected mouse model mimics the pathogenic process of human gastric MALT lymphoma development. In addition, when this bacterium infects mice orally, it forms lymphomas that cause lymphocyte infiltration. Therefore, infiltrating cells could be easily identified using an actual human gastric MALT lymphoma patient sample. Further studies using human samples are warranted.</p></sec><sec id="sec6"><title>Troubleshooting</title><sec id="sec6.1"><title>Problem 1</title><p id="p0405">When preparing a mouse gastric homogenate solution, it is possible the gastric mucosa is not sufficiently peeled off and a proper gastric homogenate Is not obtained.</p></sec><sec id="sec6.2"><title>Potential solution</title><p id="p0410">As shown in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C, sufficient stripping of the gastric mucosa with a cover glass creates enough homogenate until all epithelial tissue is stripped and only the muscularis remained (before beginning). If the homogenate is not sufficient, gastric mucosa of two or more mice can be used for stripping.</p></sec><sec id="sec6.3"><title>Problem 2</title><p id="p0415">The tissue sample dried out, and the subsequent antibody staining was significantly reduced.</p></sec><sec id="sec6.4"><title>Potential solution</title><p id="p0420">After washing with 1&#x000d7; PBS, remove the excess liquid, and quickly wipe the area around the tissue sample with a paper towel. Take special care to not dry the surface of the sample (<xref rid="sec3" ref-type="sec">step-by-step method details</xref>. 9, 11, 13, 15).</p></sec><sec id="sec6.5"><title>Problem 3</title><p id="p0425">Air bubbles are formed when adding the fluorescent mounting medium to the stained sample, hindering the capture of high-quality images with a confocal microscope.</p></sec><sec id="sec6.6"><title>Potential solution</title><p id="p0430">If there are fluorescent encapsulant bubbles on the stained tissue sample, use a pipetman to thoroughly remove them before placing the coverslip and observing with a confocal microscope. This will help obtain high-quality pictures without the influence of air bubbles (<xref rid="sec3" ref-type="sec">step-by-step method details</xref> 15).</p></sec><sec id="sec6.7"><title>Problem 4</title><p id="p0435">No positive signals are observed after staining the tissue section with antibody (<xref rid="sec3" ref-type="sec">step-by-step method details</xref> 11).</p></sec><sec id="sec6.8"><title>Potential solution</title><p id="p0440">If positive signals are not observed after antibody staining, increase the concentration of the antibody.</p></sec><sec id="sec6.9"><title>Problem 5</title><p id="p0445">PCI mixture is not always finely separated at 25:24:1 (Preparation 2, step 16)</p></sec><sec id="sec6.10"><title>Potential solution</title><p id="p0450">This product has two layers. The upper layer is the TE layer, which acts as an antioxidant. The lower layer is the PCI mixture. However, if it is not in two layers, allow it to stand until the layers separate and use the lower layer.</p></sec></sec><sec id="sec7"><title>Resource availability</title><sec id="sec7.1"><title>Lead contact</title><p id="p0455">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Koji Yamamoto (<ext-link ext-link-type="uri" xlink:href="mailto:kyama@pop.med.hokudai.ac.jp" id="intref0010">kyama@pop.med.hokudai.ac.jp</ext-link>).</p></sec><sec id="sec7.2"><title>Materials availability</title><p id="p0460">This study did not generate new unique reagents.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib16"><element-citation publication-type="journal" id="optgFqAog3nf4"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>P.</given-names></name><name><surname>Schmausser</surname><given-names>B.</given-names></name><name><surname>G&#x000f6;beler-Kolve</surname><given-names>M.</given-names></name><name><surname>M&#x000fc;ller-Hermelink</surname><given-names>H.K.</given-names></name><name><surname>Eck</surname><given-names>M.</given-names></name></person-group><article-title>Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express Toll-like receptor 4 in contrast to other lymphomas infiltrating the stomach.</article-title><source>Ann. Oncol.</source><volume>19</volume><year>2008</year><fpage>566</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">18042837</pub-id></element-citation></ref><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Ben Suleiman</surname><given-names>Y.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Nishiumi</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Mimura</surname><given-names>T.</given-names></name><name><surname>Nobutani</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Takenaka</surname><given-names>M.</given-names></name><name><surname>Aoganghua</surname><given-names>A.</given-names></name><name><surname>Miki</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice</article-title><source>Mucosal Immunol.</source><volume>5</volume><year>2012</year><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">22089027</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>El-Zaatari</surname><given-names>M.</given-names></name><name><surname>Kao</surname><given-names>J.Y.</given-names></name><name><surname>Tessier</surname><given-names>A.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Hayes</surname><given-names>M.M.</given-names></name><name><surname>Fontaine</surname><given-names>C.</given-names></name><name><surname>Eaton</surname><given-names>K.A.</given-names></name><name><surname>Merchant</surname><given-names>J.L.</given-names></name></person-group><article-title>Gli1 deletion prevents <italic>Helicobacter</italic>-induced gastric metaplasia and expansion of myeloid cell subsets</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e58935</object-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Lina</surname><given-names>T.T.</given-names></name><name><surname>Pinchuk</surname><given-names>I.V.</given-names></name><name><surname>House</surname><given-names>J.</given-names></name><name><surname>Yamaoka</surname><given-names>Y.</given-names></name><name><surname>Graham</surname><given-names>D.Y.</given-names></name><name><surname>Beswick</surname><given-names>E.J.</given-names></name><name><surname>Reyes</surname><given-names>V.E.</given-names></name></person-group><article-title>CagA-dependent downregulation of B7-H2 expression on gastric mucosa and inhibition of Th17 responses during <italic>Helicobacter pylori</italic> infection</article-title><source>J.&#x000a0;Immunol.</source><volume>191</volume><year>2013</year><fpage>3838</fpage><lpage>3846</lpage><pub-id pub-id-type="pmid">23997227</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="optloqp2CrTCW"><person-group person-group-type="author"><name><surname>Mimura</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Nishiumi</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Nobutani</surname><given-names>K.</given-names></name><name><surname>Takenaka</surname><given-names>M.</given-names></name><name><surname>Suleiman</surname><given-names>Y.B.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Ota</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>IFN-gamma plays an essential role in the pathogenesis of gastric lymphoid follicles formation caused by <italic>Helicobacter suis</italic> infection.</article-title><source>FEMS Immunol. Med. Microbiol.</source><volume>63</volume><year>2011</year><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">21631601</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Murayama</surname><given-names>S.Y.</given-names></name><name><surname>Serizawa</surname><given-names>H.</given-names></name><name><surname>Sekiya</surname><given-names>Y.</given-names></name><name><surname>Eguchi</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Nishikawa</surname><given-names>K.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>T.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name><etal/></person-group><article-title><italic>Candidatus</italic> Helicobacter heilmannii" from a cynomolgus monkey induces gastric mucosa-associated lymphoid tissue lymphomas in C57BL/6 mice</article-title><source>Infect. Immun.</source><volume>75</volume><year>2007</year><fpage>1214</fpage><lpage>1222</lpage><pub-id pub-id-type="pmid">17194807</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Okamura</surname><given-names>T.</given-names></name><name><surname>Iwaya</surname><given-names>Y.</given-names></name><name><surname>Yokosawa</surname><given-names>S.</given-names></name><name><surname>Suga</surname><given-names>T.</given-names></name><name><surname>Arakura</surname><given-names>N.</given-names></name><name><surname>Matsumoto</surname><given-names>T.</given-names></name><name><surname>Ogiwara</surname><given-names>N.</given-names></name><name><surname>Higuchi</surname><given-names>K.</given-names></name><name><surname>Ota</surname><given-names>H.</given-names></name><name><surname>Tanaka</surname><given-names>E.</given-names></name></person-group><article-title>A case of <italic>Helicobacter heilmannii</italic>-associated primary gastric mucosa-associated lymphoid tissue lymphoma achieving complete remission after eradication</article-title><source>Clin. J. Gastroenterol.</source><volume>6</volume><year>2013</year><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">26181403</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>O'Rourke</surname><given-names>J.L.</given-names></name><name><surname>Solnick</surname><given-names>J.V.</given-names></name><name><surname>Neilan</surname><given-names>B.A.</given-names></name><name><surname>Seidel</surname><given-names>K.</given-names></name><name><surname>Hayter</surname><given-names>R.</given-names></name><name><surname>Hansen</surname><given-names>L.M.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name></person-group><article-title>Description of '<italic>Candidatus</italic> Helicobacter heilmannii' based on DNA sequence analysis of 16S rRNA and urease genes</article-title><source>Int. J. Syst. Evol. Microbiol.</source><volume>54</volume><year>2004</year><fpage>2203</fpage><lpage>2211</lpage><pub-id pub-id-type="pmid">15545459</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Priestnall</surname><given-names>S.L.</given-names></name><name><surname>Wiinberg</surname><given-names>B.</given-names></name><name><surname>Spohr</surname><given-names>A.</given-names></name><name><surname>Neuhaus</surname><given-names>B.</given-names></name><name><surname>Kuffer</surname><given-names>M.</given-names></name><name><surname>Wiedmann</surname><given-names>M.</given-names></name><name><surname>Simpson</surname><given-names>K.W.</given-names></name></person-group><article-title>Evaluation of "<italic>Helicobacter heilmannii</italic>" subtypes in the gastric mucosas of cats and dogs</article-title><source>J.&#x000a0;Clin. Microbiol.</source><volume>42</volume><year>2004</year><fpage>2144</fpage><lpage>2151</lpage><pub-id pub-id-type="pmid">15131182</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>W.</given-names></name><name><surname>Takaishi</surname><given-names>S.</given-names></name><name><surname>Muthupalani</surname><given-names>S.</given-names></name><name><surname>Pritchard</surname><given-names>D.M.</given-names></name><name><surname>Whary</surname><given-names>M.T.</given-names></name><name><surname>Rogers</surname><given-names>A.B.</given-names></name><name><surname>Fox</surname><given-names>J.G.</given-names></name><name><surname>Betz</surname><given-names>K.S.</given-names></name><name><surname>Kaestner</surname><given-names>K.H.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Conditional deletion of IkappaB-kinase-beta accelerates <italic>Helicobacter</italic>-dependent gastric apoptosis, proliferation, and preneoplasia</article-title><source>Gastroenterology</source><volume>138</volume><year>2010</year><fpage>1022</fpage><lpage>1034.e1</lpage><pub-id pub-id-type="pmid">19962981</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Shigematsu</surname><given-names>Y.</given-names></name><name><surname>Niwa</surname><given-names>T.</given-names></name><name><surname>Rehnberg</surname><given-names>E.</given-names></name><name><surname>Toyoda</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>S.</given-names></name><name><surname>Mori</surname><given-names>A.</given-names></name><name><surname>Wakabayashi</surname><given-names>M.</given-names></name><name><surname>Iwakura</surname><given-names>Y.</given-names></name><name><surname>Ichinose</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>Interleukin-1beta induced by <italic>Helicobacter pylori</italic> infection enhances mouse gastric carcinogenesis</article-title><source>Cancer Lett.</source><volume>340</volume><year>2013</year><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">23920123</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="optVXSSWo2ATu"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Nishiumi</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Klimatcheva</surname><given-names>E.</given-names></name><name><surname>Pandina</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Matsui</surname><given-names>H.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Zauderer</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by <italic>Helicobacter</italic> infection.</article-title><source>Mucosal Immunol</source><volume>7</volume><year>2014</year><fpage>1244</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">24646940</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Nishitani</surname><given-names>Y.</given-names></name><name><surname>Nishiumi</surname><given-names>S.</given-names></name><name><surname>Miki</surname><given-names>I.</given-names></name><name><surname>Takenaka</surname><given-names>M.</given-names></name><name><surname>Nobutani</surname><given-names>K.</given-names></name><name><surname>Mimura</surname><given-names>T.</given-names></name><name><surname>Ben Suleiman</surname><given-names>Y.</given-names></name><name><surname>Mizuno</surname><given-names>S.</given-names></name><etal/></person-group><article-title><italic>Helicobacter suis</italic> KB1 derived from pig gastric lymphoid follicles induces the formation of gastric lymphoid follicles in mice through the activation of B cells and CD4 positive cells</article-title><source>Microbes Infect</source><volume>13</volume><year>2011</year><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">21397035</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Kondo</surname><given-names>Y.</given-names></name><name><surname>Ohnishi</surname><given-names>S.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Sugiyama</surname><given-names>T.</given-names></name><name><surname>Sakamoto</surname><given-names>N.</given-names></name></person-group><article-title>The TLR4&#x02013;TRIF&#x02013;type 1 IFN&#x02013;IFN-&#x003b3; pathway is crucial for gastric MALT lymphoma formation after <italic>Helicobacter suis</italic> infection</article-title><source>iScience</source><volume>24</volume><year>2021</year><fpage>103064</fpage><pub-id pub-id-type="pmid">34585114</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Nishiumi</surname><given-names>S.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Matsui</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Dohi</surname><given-names>T.</given-names></name><name><surname>Okada</surname><given-names>T.</given-names></name><name><surname>Kakimoto</surname><given-names>K.</given-names></name><name><surname>Hoshi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Interferon-gamma-producing B cells induce the formation of gastric lymphoid follicles after <italic>Helicobacter suis</italic> infection</article-title><source>Mucosal Immunol.</source><volume>8</volume><year>2015</year><fpage>279</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">25073677</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability" id="da0010"><title>Data and code availability</title><p id="p0030">All data reported in this paper will be shared by the lead contact upon request.</p><p id="p0035">This paper does not report original code.</p><p id="p0040">Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0470">This study was supported in part by grants from the Japan Agency for Medical Research and Development (<funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009619</institution-id><institution>AMED</institution></institution-wrap></funding-source>; grant number 18ck0106267h0002) [T.S.]), <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001691</institution-id><institution>JSPS</institution></institution-wrap></funding-source> KAKENHI (grant numbers 15K19092, 17K15684, 19K07553 [K.Y.]), and <funding-source id="gs3">Health Labour Sciences Research Grant</funding-source> (grant number 19HA1007 [T.S.]).</p><sec id="sec9"><title>Author contributions</title><p id="p0475">K.Y. and Y.K. designed the study. K.Y. and Y.K. performed the experiments. K.Y. performed the animal experiments. Y.K. and T.S. provided essential materials and contributed to data-related discussions. K.Y., Y.K., T.S., and N.S. interpreted the experimental data. K.Y., Y.K., and T.S. wrote the manuscript. N.S. critically revised the manuscript and supervised the study.</p></sec><sec sec-type="COI-statement" id="sec10"><title>Declaration of interests</title><p id="p0480">The authors declare no competing interests.</p></sec></ack></back></article>